Solid Phase Extraction - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The solid phase extraction market size was valued at USD 1.87 billion in 2025 and is estimated to grow from USD 1.94 billion in 2026 to reach USD 2.42 billion by 2031, at a CAGR of 4.54% during the forecast period (2026-2031). This report is Segmented by Type (SPE Cartridges, SPE Disks, and Other Type Segments), Application (Pharmaceutical Industries, Academic and Research Institutes, and More), Organization Size (Small and Medium Organizations and Large Organizations), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Solid Phase Extraction Market Trends and Insights

Rising Demand for High-Purity Sample Preparation in Pharmaceuticals

Pharmaceutical bioanalysis is asking for cleaner sample preparation because newer drug types are harder to handle than standard small molecules. Oligonucleotide therapeutics, antibody drug conjugates, and cell and gene therapy programs need extraction methods that can deal with tissue homogenates, whole blood, and other difficult matrices. Biotage introduced Biotage Oligo SPE in June 2025 with mixed-mode weak anion exchange chemistry and pore design aimed at oligonucleotide work, and the company stated that the product delivered up to 40 times greater LC-MS/MS signal sensitivity than competitor methods in tissue biodistribution studies. Phenomenex followed in September 2025 with Clarity OTX Pro, which the company said delivered 90% recovery from complex biological matrices without method re-optimization. These launches show that the solid phase extraction market is not only growing with pharmaceutical volumes but is also moving toward higher-value sorbents designed for specific therapeutic modalities.

Tighter Environmental and Food Safety Compliance Requirements

Environmental and food safety rules are creating one of the clearest near-term demand triggers for the solid phase extraction market. The US EPA finalized Method 1633 in January 2024, and the method covers 40 PFAS compounds across non-potable water, soil, biosolids, and tissue matrices using SPE with WAX cartridges and graphitized carbon black cleanup. In Europe, the Drinking Water Directive set binding PFAS limits and required member-state compliance by January 2026, which created a direct buying event for validated PFAS-grade SPE products across laboratories. These mandates also narrow supplier choice because only low-residual, pre-verified cartridges can reliably meet strict acceptance criteria in regulated testing. The same pattern extends into food testing as pesticide monitoring lists continue to expand, which keeps routine sample preparation demand active in regulated laboratories.

High Capital Cost of Automated SPE Platforms and Ancillary Equipment

Automated SPE systems still face a meaningful adoption barrier because full workstation setups can be expensive for many laboratories. Fully integrated systems, including solvent delivery, fraction collection, evaporation, and downstream interfacing capabilities, can exceed USD 100,000 per installation. This burden is heavier for smaller contract testing laboratories and academic facilities that do not buy instruments through large procurement programs. Vendors are introducing smaller systems such as Biotage's PrepXpert-8, but lower-volume automation does not fully solve the economics gap for the most cost-sensitive users. The result is a two-speed adoption pattern inside the solid phase extraction market, where large regulated labs automate faster and smaller users stay with manual workflows.

Other drivers and restraints analyzed in the detailed report include:

• Shift Toward Automation and High-Throughput Laboratory Workflows
• Adoption of Novel Sorbent Chemistries for Complex Matrices
• Method Development Complexity Across Diverse Sample Matrices

Segment Analysis

SPE cartridges held 45.90% of solid phase extraction market share in 2025, which kept them as the leading type because they combine broad chemistry choice with compatibility across manual and automated workflows. The format remains difficult to displace because cartridges are available in many volume ranges and support sorbents such as C18, HLB, WAX, SAX, SCX, mixed-mode, and application-specific chemistries. Regulatory methods continue to reinforce this position because EPA Method 1633 and other compliance frameworks are centered on cartridge-based sample preparation for PFAS and related testing needs. The 2025 launches of Biotage Oligo SPE and Phenomenex Clarity OTX Pro also show that cartridges are still where suppliers place premium pharmaceutical innovation. That pricing power matters because the solid phase extraction industry is not relying only on unit growth, but also on a richer product mix within cartridges.

SPE disks are projected to expand at a 6.10% CAGR through 2031, making them the fastest-growing type as large-volume aqueous testing becomes more common. Their advantage is speed because they can process high sample volumes at stronger flow rates than many cartridge setups, which is useful in water monitoring programs scaling PFAS workloads. TThis trend directly aligns with environmental testing demand, where batch efficiency and shorter extraction times deliver clear operational value. MACHEREY-NAGEL also plans to introduce a 96-well SquareWell format in 2025, increasing per-well sample volume while maintaining compatibility with existing automated systems. This development indicates that throughput-oriented format innovation is expanding beyond conventional cartridges. Other types, such as 96-well plates and pipette-tip formats, are also gaining ground in genomics and proteomics workflows, where miniaturization and robotic handling are more important than bulk liquid processing.

Complete Report Scope:

• By Type
  • SPE Cartridges
  • SPE Disks
  • Other Type Segments
• By Application
  • Pharmaceutical Industries
  • Academic and Research Institutes
  • Environmental Testing
  • Hospitals and Clinics
  • Food and Beverage Testing
  • Forensic and Toxicology Testing
  • Other Application Segments
• By Organization Size
  • Small and Medium Organizations
  • Large Organizations
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.80% of revenue in 2025, which made it the leading regional block in the solid phase extraction market. The region benefits from a high concentration of pharmaceutical CROs, regulated environmental laboratories, and federally funded research infrastructure. The United States remains the core driver because EPA Method 1633 created a direct procurement requirement for WAX-based SPE workflows across PFAS testing programs. The EPA's PFAS drinking water compliance path also extends demand beyond the first purchase cycle because laboratories will continue supporting compliance needs through 2029. Canada adds support through environmental monitoring and biopharma activity, while Mexico contributes through pharmaceutical manufacturing expansion tied to regional investment flows.

Europe remained the second-largest regional contributor, with Germany, the United Kingdom, and France serving as the main revenue centers. The region's position rests on established pharmaceutical manufacturing, contract research, and food safety testing capacity. The January 2026 compliance deadline under the EU Drinking Water Directive created immediate pull for PFAS-validated SPE products across environmental laboratories. This has favored suppliers that already had verified PFAS-focused cartridge portfolios and established technical support for regulated applications.

Asia-Pacific is projected to expand at a 6.57% CAGR through 2031, making it the fastest-growing regional segment in the solid phase extraction market. Growth in the region comes from pharmaceutical manufacturing expansion, stricter environmental oversight, and a wider institutional research base. China is adding compliance demand for analytical protocols in water and soil monitoring, which follows the same regulatory pattern seen earlier in North America and Europe. Japan is also contributing, and GL Sciences reported positive FY2025 results partly linked to domestic growth in SPE cartridges and LC columns for pharmaceutical and environmental uses. India is becoming more important as a source of generic drug makers, and CROs take on more outsourced bioanalytical work that needs FDA- and EMA-aligned methods. The Middle East and Africa and South America remain smaller in scale. However, these regions are expected to record gradual growth as environmental and pharmaceutical quality systems increasingly align with international standards.

List of Companies Covered in this Report:

• Agilent Technologies
• Biotage
• GERSTEL GmbH and Co. KG
• Gilson
• GL Sciences Inc.
• Horizon Technology, Inc.
• LECO
• MACHEREY-NAGEL GmbH and Co. KG
• Merck
• Pall
• PerkinElmer
• Phenomenex, Inc.
• Restek
• Sartorius
• SCIEX
• Shimadzu
• Tecan Group
• Thermo Fisher Scientific
• Waters Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support